![Antoine Andremont](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stéphane Postic | M | 50 |
Da Volterra SA
![]() Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | 2 years |
Pierre-Alain Bandinelli | M | - |
Da Volterra SA
![]() Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Florence Séjourné | F | 52 |
Da Volterra SA
![]() Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | - |
Mohammed Khoso Baluch | M | 66 |
Da Volterra SA
![]() Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | 1 years |
Kristin Thompson | M | 41 |
Da Volterra SA
![]() Da Volterra SA BiotechnologyHealth Technology Da Volterra develops a portfolio of products in the antibacterial field, with a specific focus on antibiotic resistance. Its productDAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. The company was founded by Antoine Andremont in 2000 and is headquartered in Paris, France. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Antoine Andremont
- Personal Network